Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extracellular Vesicle—MDM2-DNA as a Potential Liquid Biopsy Biomarker for Disease Identification in Retroperitoneal Liposarcoma

21 May 2024

Abstract excerpt

OBJECTIVE: We aimed to assess the levels of MDM2 -DNA within extracellular vesicles (EVs) isolated from the serum of retroperitoneal liposarcoma (RLS) patients versus healthy donors, as well as within the same patients at the time of surgery versus postoperative surveillance visits. To determine whether EV- MDM2 may serve as a possible first-ever biomarker of liposarcoma recurrence. BACKGROUND: A hallmark of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac tumors and thrombi
Share to Extracellular vesicles in disease
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38771951
DOI: 10.1097/sla.0000000000006345

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extracellular Vesicle—MDM2-DNA as a Potential Liquid Biopsy Biomarker for Disease Identification in Retroperitoneal LiposarcomaPMID 38771951Read ↗

The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcomaSemantic proximity Read ↗

Phenotypic transition in retroperitoneal liposarcoma: Bridging well-differentiated and dedifferentiated subtypes through genomics, epigenetics, and the tumor microenvironment.Semantic proximity Read ↗

Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.Semantic proximity Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.Semantic proximity Read ↗

Dedifferentiated LiposarcomaSemantic proximity Read ↗

Prognostic potential of fusion gene analysis using plasma cell-free RNA in malignant bone and soft tissue tumoursSemantic proximity Read ↗

Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin.Semantic proximity Read ↗

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaSemantic proximity Read ↗

Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcomaSemantic proximity Read ↗

Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative SplicingSemantic proximity Read ↗

Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.